92 studies found for:    MEK Inhibitor AZD-6244
Show Display Options
Rank Status Study
1 Completed Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
Condition: Thyroid Cancer
Intervention: Biological: AZD6244
2 Recruiting MEK Inhibitor and Thoracic Radiotherapy Trial
Condition: Non Small Cell Lung Cancer
Intervention: Drug: AZD6244
3 Completed
Has Results
MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma
Conditions: Recurrent Melanoma;   Stage III Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Selumetinib
4 Terminated
Has Results
Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Condition: Recurrent Adult Diffuse Large Cell Lymphoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Selumetinib
5 Recruiting Intermittent Selumetinib for Uveal Melanoma
Condition: Uveal Melanoma
Intervention: Drug: Selumetinib
6 Unknown  A Study of Selumetinib in Patients With Kaposi's Sarcoma
Condition: AIDS-related Kaposi's Sarcoma
Intervention: Drug: Selumetinib
7 Completed A Randomized, Open Label Study to Compare the Current Phase II and Planned Phase III Capsule Formulation of AZD6244
Condition: Healthy Volunteers
Interventions: Drug: AZD6244 Dosing Period 1;   Drug: AZD6244 Dosing Period 2;   Drug: AZD6244 Dosing Period 3;   Drug: AZD6244 Dosing Period 4
8 Completed To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers
Condition: Solid Tumours
Intervention: Drug: selumetinib (oral)
9 Terminated AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Intervention: Drug: AZD6244 and sorafenib
10 Active, not recruiting AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Patients With Advanced Solid Malignancies
Conditions: Tumor;   Cancer
Intervention: Drug: AZD6244
11 Completed Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers
Condition: Solid Tumours
Intervention: Drug: [C14] selumetinib (oral)
12 Completed
Has Results
Selumetinib in Cancers With BRAF Mutations
Condition: Adult Solid Neoplasm
Intervention: Drug: Selumetinib
13 Completed
Has Results
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
Conditions: Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Selumetinib
14 Completed Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors
Conditions: Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: selumetinib;   Biological: cetuximab;   Other: laboratory biomarker analysis;   Other: pharmacological study
15 Recruiting A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers
Conditions: Triple-Negative Breast Cancer;   Squamous Cell Lung Cancer;   Non-squamous Cell Lung Cancer With KRAS Mutations;   Non-squamous Cell Lung Cancer With Wild-type KRAS
Interventions: Drug: AZD2014;   Drug: AZD6244
16 Completed Randomised Study to Compare the Efficacy of AZD6244 vs TMZ
Condition: Melanoma
Interventions: Drug: AZD6244;   Drug: Temozolomide
17 Completed Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies
Condition: Adult Solid Neoplasm
Interventions: Biological: Cixutumumab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Selumetinib
18 Completed
Has Results
MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma
Condition: Colorectal Neoplasms
Intervention: Drug: MK-2206 + AZD6244
19 Completed Dose-escalation Study to Assess Selumetinib Safety, Tolerability and PK
Condition: Healthy Volunteers Pharmacokinetic Study
Intervention: Drug: Selumetinib
20 Not yet recruiting Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Dermal Neurofibroma
Conditions: Appearance Distress;   Bothered by Itching Skin;   Cafe Au Lait Spot;   Cutaneous Neurofibroma;   Disfigurement;   Dysplasia;   Lisch Nodule;   Neurofibromatosis Type 1;   NF1 Gene Mutation;   Optic Nerve Glioma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Selumetinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.